Incidence of insignificant prostate cancer using free/total PSA: Results of a case-finding protocol on 14 453 patients

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 4, 2010, Pages 316-319

  Pepe, P ^a   Aragona, F ^a  

^a CANNIZZARO HOSPITAL   (Italy)

Author keywords

overdiagnosis and PCa; overtreatment and Pca; PCa early diagnosis; PCa screening; PSA free total

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CASE FINDING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; REPEAT PROCEDURE;

ADULT; AGED; BIOPSY; CLINICAL PROTOCOLS; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SOLUBILITY;

EID: 78649329127     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.29     Document Type: Article

References (19)

1. Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V et al. Screening of prostate cancer mortality in randomized European study. N Engl Med 2009; 360: 1320-1328.
2. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR et al. PLCO Project Team: mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
3. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 417-424.
4. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G et al. Screening decreases prostate cancer mortality: 11-year follw-up of the 1988 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311-318.
5. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in PSA screening for prostate cancer. Br J cancer 2009; 1: 1833-1838.
6. Epstein J, Walsh P, Carmichael M. Pathological and clinical findings to predict tumour extent of non palpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
7. Aragona F, Pepe P, Motta M, Saita A, Raciti G, La Rosa P et al. Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol. Eur Urol 2005; 47: 569-574.
8. Pepe P, Aragona F. Prostate needle biopsy: 12 vs 18 cores. Is it necessary? Urol Int 2005; 74: 19-22.
9. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology 2007; 70: 1131-1135.
10. Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D et al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 995-1000.
11. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennal screening using serum PSA measurement to detect prostate cancer. Cancer 2004; 100: 1397-1405.
12. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M et al. PSA best practice statement 2009 update. J Urol 2009; 182: 2232-2241.
13. Hoffman R, Clanon D, Littenberg B, Frank JJ, Peirce JCl. Using free-to-total PSA ratio to detect prostate cancer in men with nonspecific elevations of PSA levels. J Gen Intern Med 2000; 15: 739-748.
14. Chun FK, Hutterer GC, Perrotte, Gallina A, Valiquette L, Bernard F et al. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening with no evidence of prostate cancer. BJU Int 2007; 100: 37-41.
15. Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V et al. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. Urology 2009; 73: 1323-1327.
16. D'Amico AV, Renshaw AA, Cote K, Hurwitz M, Beard C, Loffredo M et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favourable intermediate-risk disease. J Clin Oncol 2004; 22: 3726-3732.
17. Pepe P, Panella P, D'Arrigo L, Savoca F, Pennisi M, Aragona F. Should men with serum PSAo4 ng/ml and normal digital rectal examination undergo a prostate biopsy? Oncology 2006; 70: 81-89.
18. Stranne J, Damber JE, Fall M, Hammarsten J, Knutson T, Peeker R. One-third of Swedish male population over 50 years of age suffers from lower urinary tract symptoms. Scand J Urol Nephrol 2009; 43: 199-205.
19. Godley PA, Carperter WR. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms. J Clin Epidemiol 2007; 60: 176-180.